Cytotoxicity and mutagenicity of frameshift-inducing agent ICR191 in mismatch repair-deficient colon cancer cells

Journal of the National Cancer Institute

Volumn 92, Issue 6, 2000, Pages 480-485

  Chen, Wei Dong ^d   Eshleman, James R ^a   Aminoshariae, M Reza ^d   Ma, Ai Hong ^d   Veloso, Neil ^d   Markowitz, Sanford D ^b,c   Sedwick, W David ^d   Veigl, Martina L ^d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

6 CHLORO 9 [3 (2 CHLOROETHYL)AMINOPROPYLAMINO] 2 METHOXYACRIDINE;

ARTICLE; BASE MISPAIRING; CARCINOGENESIS; COLON CANCER; CYTOTOXICITY; DNA REPAIR; DNA SEQUENCE; FRAMESHIFT MUTATION; HUMAN; HUMAN CELL; MUTAGENICITY; PRIORITY JOURNAL;

EID: 0034653705     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/92.6.480     Document Type: Article

References (49)

1. Eshleman JR, Markowitz SD. Microsatellite instability in inherited and sporadic neoplasms. Curr Opin Oncol 1995;7:83-9.
2. Marra G, Boland CR. Hereditary nonpolyposis colorectal cancer: the syndrome, the genes, and historical perspectives. J Natl Cancer Inst 1995;87:1114-25.
3. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87: 159-70.
4. Kolodner R. Biochemistry and genetics of eukaryotic mismatch repair. Genes Dev 1996;10: 1433-42.
5. Bhattacharyya NP, Skandalis A, Ganesh A, Groden J, Meuth M. Mutator phenotypes in human colorectal carcinoma cell lines. Proc Natl Acad Sci U S A 1994;91:6319-23.
6. Eshleman JR, Lang EZ, Bowerfind GK, Parsons R, Vogelstein B, Willson JK, et al. Increased mutation rate at the hprt locus accompanies microsatellite instability in colon cancer. Oncogene 1995;10:33-7.
7. Glaab WE, Tindall KR. Mutation rate at the hprt locus in human cancer cell lines with specific mismatch repair-gene defects. Carcinogenesis 1997;18:1-8.
8. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 1995; 268:1336-8.
9. Parsons R, Myeroff LL, Liu B, Willson JK, Markowitz SD, Kinzler KW, et al. Microsatellite stability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. Cancer Res 1995;55:5548-50.
10. Ferguson LR, Denny WA. Frameshift mutagenesis by acridines and other reversibly-binding DNA ligands. Mutagenesis 1990;5: 529-40.
11. Calos MP, Miller JH. Genetic and sequence analysis of frameshift mutations induced by ICR191. J Mol Biol 1981;153:39-64.
12. Cariello NF, Keohavong P, Kat AG, Thilly WG. Molecular analysis of complex human cell populations: mutational spectra of MNNG and ICR191. Mutat Res 1990;231:165-76.
13. Taft SA, Liber HL, Skopek TR. Mutational spectrum of ICR191 at the hprt locus in human lymphoblastoid cells. Environ Mol Mutagen 1994;23:96-100.
14. Creech HJ, Preston RK, Pek RM, O'Connell AP. Antitumor and mutagenic properties of a variety of heterocyclic nitrogen and sulfur mustards. J Med Chem 1972;15:739-46.
15. Fuscoe JC, O'Neill JP, Peck RM, Hsie AW. Mutagenicity and cytotoxicity of nineteen heterocyclic mustards (ICR compounds) in cultured mammalian cells. Cancer Res 1979;39: 4875-81.
16. 6-alkylguanine-DNA alkyltransferase. Cancer Res 1993;53:997-1003.
17. Liu N, Lamerdin JE, Tucker JD, Zhou ZQ, Walter CA, Albala JS, et al. The human XRCC9 gene corrects chromosomal instability and mutagen sensitivities in CHO UV40 cells. Proc Natl Acad Sci U S A 1997;94:9232-7.
18. Bronstein SM, Cochrane JE, Craft TR, Swenberg JA, Skopek TR. Toxicity, mutagenicity, and mutational spectra of N-ethyl-N-nitrosourea in human cell lines with different DNA repair pnenotypes. Cancer Res 1991;51: 5188-97.
19. Branch P, Hampson R, Karran P. DNA mismatch binding defects, DNA damage tolerance, and mutator phenotypes in human colorectal carcinoma cell lines. Cancer Res 1995;55:2304-9.
20. Goldmacher VS, Cuzick RA Jr, Thilly WG. Isolation and partial characterization of human cell mutants differing in sensitivity to killing and mutation by methylnitrosourea and N-methyl-N′-nitro-N-nitrosoguanidine. J Biol Chem 1986;261:12462-71.
21. Koi M, Umar A, Chauhan DP, Cherian SP, Carethers JM, Kunkel TA, et al. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N′-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation [published erratum appears in Cancer Res 1995;55:201]. Cancer Res 1994;54: 4308-12.
22. Kat A, Thilly WG, Fang WH, Longley MJ, Li GM, Modrich P. An alkylation-tolerant, mutator human cell is deficient in strand-specific mismatch repair. Proc Natl Acad Sci U S A 1993;90:6424-8.
23. Risinger JI, Umar A, Barrett JC, Kunkel TA. A hPMS2 mutant cell line is defective in strand-specific mismatch repair. J Biol Chem 1995; 270:18183-6.
24. Carethers JM, Chauhan DP, Fink D, Nebel S, Bresalier RS, Howell SB, et al. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 1999;117:123-31.
25. Fink D, Nebel S, Aebi S, Zheng H, Cenni B, Nehme A, et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res 1996;56:4881-6.
26. Fink D, Zheng H, Nebel S, Norris PS, Aebi S, Lin TP, et al. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res 1997;57:1841-5.
27. Glaab WE, Skopek TR. Cytotoxic and mutagenic response of mismatch repair-defective human cancer cells exposed to a food-associated heterocyclic amine. Carcinogenesis 1999;20:391-4.
28. DeWeese TL, Shipman JM, Larrier NA, Buckley NM, Kidd LR, Groopman JD, et al. Mouse embryonic stem cells carrying one or two detective Msh2 alleles respond abnormally to oxidative stress inflicted by low-level radiation. Proc Natl Acad Sci U S A 1998;95: 11915-20.
29. Fritzell JA, Narayanan L, Baker SM, Bronner CE, Andrew SE, Prolla TA, et al. Role of DNA mismatch repair in the cytotoxicity of ionizing radiation. Cancer Res 1997;57:5143-7.
30. Parsons R, Li GM, Longley MJ, Fang WH, Papadopoulos N, Jen J, et al. Hypermutability and mismatch repair deficiency in RER+ tumor cells. Cell 1993;75:1227-36.
31. Aebi S, Kurdi-Haidar B, Gordon R, Cenni B, Zheng H, Fink D, et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 1996;56:3087-90.
32. Shibata D, Peinado MA, Ionov Y, Malkhosyan S, Perucho M. Genomic instability in repeated sequences is an early somatic event in colorectal tumorigenesis that persists after transformation. Nat Genet 1994;6:273-81.
33. 6-methylguanine, 04-methylthymine, or the cisplatin-d(GpG) adduct. Proc Natl Acad Sci U S A 1996;93:6443-7.
34. Skopek TR, Hutchinson F. Frameshift mutagenesis of lambda prophage by 9-aminoacridine, proflavin and ICR191. Mol Gen Genet 1984;195:418-23.
35. René B, Auclair C, Paoletti C. Frameshift lesions induced by oxazolopyridocarbazoles are recognized by the mismatch repair system in Escherichia coli. Mutat Res 1988;193:269-73.
36. Modrich P, Lahue R. Mismatch repair in replication fidelity, genetic recombination, and cancer biology. Microsatellite instability and mutations of the transforming growth factor beta type 11 receptor gene in colorectal cancer. Annu Rev Biochem 1996;5:101-33.
37. Ernst JF, Hampsey DM, Sherman F. DNA sequences of frameshift and other mutations induced by ICR-170 in yeast. Genetics 1985;111: 233-41.
38. Hampsey DM, Koski RA, Sherman F. Highly mutable sites for ICR-170-induced frameshift mutations are associated with potential DNA hairpin structures: studies with SUP4 and other Saccharomyces cerevisiae genes. Mol Cell Biol 1986;6:4425-32.
39. Ripley LS. Frameshift mutation: determinants of specificity. Annu Rev Genet 1990;24: 189-213.
40. Streisinger G, Okada Y, Emrich J, Newton J, Tsugita A, Terzaghi E, et al. Frameshift mutations and the genetic code. Cold Spring Harbor Symp Quant Biol 1996;31:77-84.
41. Streisinger G, Owen J. Mechanisms of spontaneous and induced frameshift mutation in bacteriophage T4. Genetics 1985;109:633-59.
42. Kane MF, Loda M, Gaida G, Lipman J, Mishra R, Goldman H, et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 1997;57:808-811.
43. Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A 1998;95:6870-5.
44. Veigl ML, Kasturi L, Olechnowicz J, Ma AH, Lutterbaugh JD, Periyasamy S, et al. Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc Natl Acad Sci U S A 1998; 95:8698-702.
45. Eshleman JR, Markowitz SD, Donover PS, Lang EZ, Lutterbaugh JD, Li GM, et al. Diverse hypermutability of multiple expressed sequence motifs present in a cancer with microsatellite instability. Oncogene 1996;12: 1425-32.
46. Ferguson LR, van Zijl P, Baguley BC. Comparison of the mutagenicity of amsacrine with that of a new clinical analogue, CI-921. Mutat Res 1988;204:207-17.
47. Cholody WM, Hernandez L, Hassner L, Scudiero DA, Djurickovic DB, Michejda CJ. Bisimidazoacridones and related compounds: new antineoplastic agents with high selectivity against colon tumors. J Med Chem 1995;38: 3043-52.
48. Schofield PC, Robertson IG, Paxton JW, McCrystal MR, Evans BD, Kestell P, Baguley BC. Metabolism of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in cancer patients undergoing a phase 1 clinical trial. Cancer Chemother Pharmacol 1999;44:51-8.
49. Small EJ, Pippin LJ, Whisenant SP. Pyrazoloacridine for the treatment of hormone-refractory prostate cancer. Cancer Invest 1998;16: 456-61.